CSF1 and HIV-1 infection: Blocking the other Siglec molecules (Siglec-3, -5, or -9) resulted in 5–28% and 12–48% reduction of HIV-1 infection for M-CSF– and GM-CSF–derived MDMs, respectively (Fig. 4A and B).